Peripheral Arterial Disease (PAD) Treatment Devices

Boston Scientific Corp. CE mark Ranger Ranger Paclitaxel-coated PTA Balloon Cath

Boston Scientific received CE mark for the Ranger Paclitaxel-coated PTA Balloon Catheter. The technology is now in full European market launch. 

May 16, 2014 — In a move to expand significantly its portfolio of solutions for peripheral interventions, Boston Scientific Corp. has entered into a definitive agreement to acquire the interventional division of Bayer AG for $415 million...

The U.S. Food and Drug Administration (FDA) approved Abbott’s Supera Peripheral Stent System to treat people with blocked blood vessels in the upper leg caused by peripheral artery disease (PAD).

The U.S. Food and Drug Administration (FDA) cleared Cardiovascular Systems Inc.’s Diamondback 360 60 cm Peripheral Orbital Atherectomy Systems (OAS) for the treatment of peripheral arterial disease (PAD).

Medtronic IN.PACT Admiral Drug Coated Balloon Peripheral Artery Disease Treatmen
Presented for the first time at the 2014 Transcatheter Cardiovascular Therapeutics (TCT) conference, the latest clinical and economic data on the IN.PACT...
More than 40 percent of Americans aged 40 and older have experienced one or more of the most common symptoms[1] of peripheral arterial disease (PAD).
The first large prospective study to examine the effectiveness of laser atherectomy in the treatment of femoropopliteal in-stent restenosis (ISR) found that...
Covidien TurboHawk Clinical Study Directional Atherectomy Effective PAD Therapy
Directional atherectomy is safe and effective as a frontline therapy for the treatment of peripheral arterial disease (PAD), according to a landmark Covidien...
The Arrow GPSCath Balloon Dilatation Catheters is designed for use with 0.014-inch guidewires and in 150-cm length. These products enable a
Cordis Corp.'s Saber PTA (percutaneous transluminal angioplasty) dilatation catheter is for the treatment of patients with peripheral...
Cardiovascular Systems Inc.’s Diamondback 360 60 cm Peripheral Orbital Atherectomy Systems (OAS) are for the treatment of peripheral...
Boston Scientific's OffRoad Re-Entry Catheter System treats complete arterial blockages in the major arteries of the legs. ...

Articles

More than 40 percent of Americans aged 40 and older have experienced one or more of the most common symptoms[1] of peripheral arterial disease (PAD).
The first large prospective study to examine the effectiveness of laser atherectomy in the treatment of femoropopliteal in-stent restenosis (ISR) found that...
Covidien TurboHawk Clinical Study Directional Atherectomy Effective PAD Therapy
Directional atherectomy is safe and effective as a frontline therapy for the treatment of peripheral arterial disease (PAD), according to a landmark Covidien...
Directional atherectomy is safe and effective as a frontline therapy for the treatment of peripheral arterial disease (PAD), according to a landmark Covidien...

Video Center

By Dave Fornell, editor of DAIC Magazine The key take away messages from the 26th annual...
3 weeks 5 days ago
As technology continues to advance for all diagnostic imaging modalities, it sometimes reminds me...
7 weeks 8 hours ago
The Society of Cardiovascular Computed Tomography (SCCT) annual meeting July 10-13 in San Diego...
12 weeks 5 days ago
This webinar will discuss why contemporary adult cardiac interventions require significant ionizing radiation with potential health risks to both the patient...
This webinar explained the benefits of better access, productivity and revenue cycle efficiency in a modern cardiovascular information system (CVIS...
The webinar "PET/CT: A New Frontier" discusses potential benefits of digital relative to analog PET/CT. The session will discuss how digital PET can improve...

Comparison Charts

Sorry there is no data available